Dr. Meghan Berkenstock graduated from Drexel University College of Medicine in 2011. She completed her ophthalmology residency at the Drexel University/Hahnemann Hospital program followed by an additional year of subspecialty training in Ocular Immunology at the Jules Stein Eye Institute at the University of California, Los Angeles. After graduation, she joined the faculty of the Wilmer Eye Institute of the Johns Hopkins School of Medicine where she is currently an Associate Professor of Ophthalmology.

Over the last 9 years, she has established a research focus on risk reduction and quality assurance initiatives in the care of patients with uveitis. She has implemented several initiatives to improve laboratory monitoring and understanding barriers to care in patients on immunosupressive medications. The majority of her research focuses on identifying ocular adverse events (IRAE) associated with use of immunotherapy and targeted antineoplastic agents. She is a member and the only ophthalmologist on the National Comprehensive Cancer Network Panel on developing guidelines to treat IRAEs. Her most cherished title is Mother of 4.

Financial disclosure: Dr. Berkenstock has/had an affiliation (financial or otherwise) with a commercial organization:

1. AbbVie Inc.
2. Eyepoint Pharamceuticals
3. National Comprehensive Cancer Network 
4. Sanofi Inc.